Prestige Consumer Healthcare (NYSE:PBH) Upgraded at Raymond James

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was upgraded by investment analysts at Raymond James to a "moderate buy" rating in a note issued to investors on Thursday,Zacks.com reports.

PBH has been the topic of several other reports. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Wednesday. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. DA Davidson restated a "buy" rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.25.

Prestige Consumer Healthcare Stock Up 0.1 %

Shares of NYSE:PBH traded up $0.06 during midday trading on Thursday, reaching $78.72. The company's stock had a trading volume of 604,977 shares, compared to its average volume of 253,877. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a 50 day moving average of $79.25 and a 200-day moving average of $73.10. The firm has a market capitalization of $3.89 billion, a P/E ratio of 19.15, a PEG ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 12-month low of $57.95 and a 12-month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analysts' expectations of $282.09 million. During the same quarter in the prior year, the company earned $1.07 earnings per share. The business's revenue was down .9% compared to the same quarter last year. On average, research analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider William P'pool sold 8,987 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares of the company's stock, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently added to or reduced their stakes in PBH. Boston Trust Walden Corp bought a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at $41,785,000. Ariel Investments LLC increased its holdings in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock worth $195,204,000 after purchasing an additional 274,212 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company's stock worth $90,891,000 after buying an additional 272,773 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company's stock valued at $142,827,000 after buying an additional 171,357 shares during the last quarter. Finally, F M Investments LLC purchased a new position in Prestige Consumer Healthcare during the 2nd quarter valued at approximately $11,162,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.